chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Flu like symptoms; PAIN IN HANDS HERE AND THERE; This spontaneous case was reported by a consumer and describes the occurrence of INFLUENZA LIKE ILLNESS (Flu like symptoms) and PAIN IN EXTREMITY (PAIN IN HANDS HERE AND THERE) in an adult female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) solution for injection for Rheumatoid arthritis.    Concomitant products included COVID-19 VACCINE NRVV AD26 (JNJ 78436735) for COVID-19 vaccination.   On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form and ADALIMUMAB (HUMIRA) (Subcutaneous) at an unspecified dose. On an unknown date, the patient experienced INFLUENZA LIKE ILLNESS (Flu like symptoms) and PAIN IN EXTREMITY (PAIN IN HANDS HERE AND THERE). At the time of the report, INFLUENZA LIKE ILLNESS (Flu like symptoms) had resolved and PAIN IN EXTREMITY (PAIN IN HANDS HERE AND THERE) had not resolved.            No treatment medications were reported.  The reporter's causality for the events of pain in hand and flu like symptoms was not provided.  It was unknown if patient was enrolled in a COVID-19 Vaccine Trial.   Reporter did not allow further contact
There was 1 doctor that got blood clot after receiving moderna vaccine; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of THROMBOSIS (There was 1 doctor that got blood clot after receiving moderna vaccine) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Unknown) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage form. On an unknown date, the patient experienced THROMBOSIS (There was 1 doctor that got blood clot after receiving moderna vaccine) (seriousness criterion medically significant). At the time of the report, THROMBOSIS (There was 1 doctor that got blood clot after receiving moderna vaccine) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were provided. Treatment medications was not provided.  Agent crosslinked this case to MOD21-132671.  Very limited information regarding this event has been provided at this time. Further information regarding temporal association is necessary. Further information has been requested.   Reporter did not allow further contact; Sender's Comments: Very limited information regarding this event has been provided at this time. Further information regarding temporal association is necessary. Further information has been requested.
This is a spontaneous report from a contactable Nurse received via a sales representative. A 18-year-old female patient received 2nd dose of TRUMENBA, via an unspecified route of administration on 23May2018 for immunization. The patient medical history and concomitant medications were not reported. The patient previously took first dose TRUMENBA for immunization on 14Nov2017. She had her 2nd dose of meningococcal group B rlp2086 on 23May2018 approximately 6 months later at around 9 AM. Later in the day on 23May2018, she got a headache and didn't feel great so she took ADVIL and went to sleep, she had no appetite. When she woke up she had severe swelling of her arm and fainted. She was taken to the ER where she was checked out and given a diagnosis of syncope. The outcome of the event was unknown.
VAERS completed because of being Tested positive for COVID-19 infection 14 or more days after being fully vaccinated. 1st dose 03/27/21 2nd dose04/19/21 Diagnosed covid positive:08/26/21 Symptom onset:08/25/21 Exposure: Symptoms:fever. cough,fatigue, loss of smell/taste, sore throat,chills, runny nose.
This spontaneous report as received from a nurse via company representative refers to a 46 year old immunocompromised female patient. The patient's concurrent condition included colitis. The patient's concomitant medications, drug reactions or allergies were not reported. On 30-SEP-2015, the patient was tested for immunity of Hepatits B for unspecified reasons. The results of test were Hepatitis B surface antigen of "0.2" and non-reactive. On 08-OCT-2015, the patient was vaccinated with the first dose of RECOMBIVAX HB for prophylaxis (dosage, route of administration, lot# and expiration date were unknown). On 8-DEC-2015, the patient was vaccinated with the second dose and on 9-MAY-2016 was vaccinated with the third dose of RECOMBIVAX HB. In approximately 2016 for unspecified reasons, the patient was tested for immunity of Hepatitis B and the results were "non-reactive". On 15-SEP-2016, the patient was vaccinated with the fourth dose of RECOMBIVAX HB. On 17-NOV-2016, the patient was vaccinated with the fifth dose and on 16-MAR-2017 was vaccinated with the sixth dose of RECOMBIVAX HB. On 11-JUL-2017, the patient was tested for immunity of Hepatitis B and the result was "0.1" and non-reactive. On 25-JUL-2017, the patient was tested for immunity of Hepatitis B for unspecified reasons and the result was "0.1" and non-reactive. The outcome of negative Hepatitis B surface antibody and non-responder of the therapy with RECOMBIVAX HB were unknown. The relatedness between the events and therapy with RECOMBIVAX HB were not reported.
This spontaneous report as received from a Licensed Practical Nurse refers to an unspecified number of patients of unknown age and gender. Concomitant medication and current conditions were not reported. On an unknown date, the patients were vaccinated with an improperly stored dose of PROQUAD (Merck) (route not reported), lot number reported as: K008872 and expiration date: 19-DEC-2015). Concomitant medication was not provided. No adverse effects reported. This is one of several reports from the same reporter. Additional information has been requested.
Patient received an adult dose of Pfizer instead of the pediatric dose.   Managers, Pediatric Doc, Peds Covid physician (Doctor Notified) Had patient stay a full hour to be monitored.  Mom is a nurse and she called her peds doc. Had pharmacist also speak with mom.  Reassured mom and told her that we would keep her even longer than normal.   Child was playful and not exhibiting any adverse reactions.
Pain in left arm; Rash in neck and upper body; heat and itching in area; heat and itching in area; This is a spontaneous report received from a contactable consumer reporting for self. A 43-years-old female patient received the second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE), via an unspecified route of administration, administered in Arm Left on 07Mar2021 11:00 (Batch/Lot number was not reported) as single dose for covid-19 immunisation. Patient received the first dose on 14Feb2021. Medical history included asthma, lactose intolerance. Patient had allergies to Bactrim, Sudafed. Concomitant medications included cetirizine hydrochloride (ZYRTEC [CETIRIZINE HYDROCHLORIDE]), diphenhydramine hydrochloride (BENADRYL), ibuprofen, colecalciferol (VITAMIN D [COLECALCIFEROL]), vitamins. The patient experienced Pain in left arm, Rash in neck and upper body, heat and itching in area on 08Mar2021 16:00. Outcome of events was not recovered.   Information on the lot/batch number has been requested.
broke out in a sweat/very diaphoretic; the room turned a yellow color and she knew she was getting ready to pass out; the room turned a yellow color and she knew she was getting ready to pass out; blood pressure was lower than normal; This is a spontaneous report from a contactable nurse (parent reporting for her daughter). A 40-year-old female patient received the first dose BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE), via an unspecified route of administration on an unknown date as a single dose for Covid-19 immunization. Medical history included allergic to bee stings and carries an EpiPen. The patient's concomitant medications were not reported. On an unspecified date, within the first 15 minutes of vaccination the patient broke out in a sweat and she had to lay down. They got her a coke and she felt a little better. The patient works in a dental office and 2.5 hours later, she was working on a patient in her dental office and she broke out in a sweat again, very diaphoretic, and the patient reported that the room turned a yellow color and she knew she was getting ready to pass out, but they took her in a room and put her in a reclining chair and let her stay there for 1 hour. They kept a wet towel on the patient's forehead. The caller said that they checked her daughter's blood pressure and it was lower than normal when checked. The patient was going to be receiving her second dose in an hour. The clinical outcome of the events was unknown.   The lot number for the vaccine, BNT162B2, was not provided and will be requested during follow up.
Patient experienced lump in her upper left arm with decreased range of motion 2 days after vaccination. Patient did not report event to the pharmacy because she thought it would get better. Vaccination was given on 6/12/2019 and reported to the pharmacy 7/8/2019; pt will follow up with her PCP on her upcoming appointment.
Left shoulder approximately 5 cm redness and tenderness around immunization site. In addition fever/chills 24-36 hours after vaccination - but may be due to possible UTI (mild sx).
Was walking to check out of clinic and became dizzy.  Appeared to lose consciousness twice for less than 5 seconds.  PA helped patient to lie down on the floor and she felt better in minutes.
This case was reported by a consumer via call center representative and described the occurrence of injection site pain in a 4-year-old female patient who received KINRIX. Concomitant products included MMR. On 4th November 2016, the patient received KINRIX (intramuscular). On 4th November 2016, immediately after receiving KINRIX, the patient experienced injection site pain, throat pain, walking difficulty, facial swelling and ear pain. In November 2016, the patient experienced injection site wheal and injection site warmth. The patient was treated with epinephrine, steroid shot and BENADRYL. On an unknown date, the outcome of the injection site pain was recovering/resolving and the outcome of the injection site wheal and injection site warmth were not recovered/not resolved and the outcome of the throat pain, facial swelling and ear pain were recovered/resolved and the outcome of the walking difficulty was unknown. The reporter considered the injection site pain, injection site wheal, injection site warmth, throat pain, walking difficulty, facial swelling and ear pain to be related to KINRIX. Additional details were provided as follows: At 12:30, the patient received KINRIX in her right thigh. The batch number of the KINRIX was unknown. On the same day the patient received MMR vaccine in her Left thigh. On the same day of vaccination, right away the patient started complaining that her right leg hurt, and within 10 min she couldn't walk. The patient went home and was fine until 5:30 that evening, several hours after vaccination (when she had to lie down) was complaining of an earache. The reporter went to get some medication, thinking the patient might be getting sick. Five hours after vaccination, the patient experienced swollen face and sore throat. The reporter called around to urgent care offices until she spoke with a nurse and was told to administer 1 table spoon of BENADRYL and took the patient to the emergency room. At the emergency room the patient was treated with epinephrine and a steroid shot right away. The patient was observed for about 6 hours before being released home. At the time of reporting, less than week after vaccination, the patient had a hot welt the size of a softball on her right thigh. The patient was walking, but her leg was tender and she was sitting a lot more than normal. The patient's mother did not know when the welt appeared, but she did not see it when she took the patient to the emergency room.
Shoulder to elbow it was red; Warm to the touch; 3-4 inch area around injection site; Red / 3-4 inch area around injection site; Itching; Pain; Headache; Unspecified gastrointestinal issues (GI); This case was reported by a pharmacist via call center representative and described the occurrence of erythema in a 85-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   The patient's past medical history included shingles. Previously administered products included Shingrix with an associated reaction of herpes zoster (1st dose received on unknown date. refer case US2020AMR203749).   On 8th October 2020, the patient received the 2nd dose of Shingrix. In October 2020, less than a week after receiving Shingrix, the patient experienced erythema, injection site warmth, injection site erythema, pruritus, pain, headache and gastrointestinal discomfort. On an unknown date, the outcome of the erythema, pruritus, pain and headache were not recovered/not resolved and the outcome of the injection site warmth was unknown and the outcome of the injection site erythema and gastrointestinal discomfort were recovered/resolved.   It was unknown if the reporter considered the erythema, injection site warmth, injection site erythema, pruritus, pain, headache and gastrointestinal discomfort to be related to Shingrix.  Additional details were as follows: Pharmacist reported that an 85 year old female patient received the 2nd dose of shingrix on 8th October,2020 and experienced events like her shoulder to elbow it was red and has gone down but it was still red and warm to the touch and  3-4 inch area around injection site. Also she experienced some itching, pain, headache and unspecified gastrointestinal issues (GI) and The GI issues have resolved. The itching, pain, and headache are ongoing. The reporter consented to follow up. This case has been linked to US2020AMR203749 case.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020AMR203749:
First shot: immediately dry mouth and itchy throat.  Within 1/2 hour eyesight was very slightly blurry.  Second dose: Immediately after receiving shot had itchy inner ears and a dry, itchy throat.  Within 1 hour after my face swelled up and I looked sunburned an had no wrinkles. (I am 51, so I definitely have wrinkles and all the lines in my face disappeared.) Swelling and symptoms were gone within 4 hours.
I had a really mild reaction; This is a spontaneous report from a contactable consumer. A patient of unspecified age and gender received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Solution for injection; Batch/Lot number, Expiry date was not reported), via an unspecified route of administration on an unspecified date as dose 1, single for covid-19 immunisation. Medical history included chronic pain, autoimmune disorder from an unknown date and unknown if ongoing. The patient concomitant medications were not reported. Caller called seeking assistance with the medication flector topical system. During the call caller stated. I have chronic pain. Caller later stated on the call. I had the Pfizer COVID -19 vaccination and I just have to say I have a bad reaction to everything, and I had a really mild reaction, and I was just glad I went with Pfizer and not the others. It was great I had very minimal experience with it. I have an autoimmune disorder which is why I have the chronic pain, normally I'm on immunosuppressant medication and so I had to go off of that in order to get the vaccine and I was like oh boy it's probably gonna hit me like a ton of bricks. And you know I was pleasantly surprised that it was great. The outcome of events was unknown.   No follow-up attempts are possible. information about lot/batch number cannot be obtained.
This case was reported by a consumer via call center representative and described the occurrence of heart attack in a male patient who received SHINGRIX for prophylaxis. Co-suspect products included SHINGRIX for prophylaxis. Concurrent medical conditions included type II diabetes mellitus. On an unknown date, the patient received the 1st dose of SHINGRIX and the 2nd dose of SHINGRIX. On an unknown date, unknown after receiving SHINGRIX and not applicable after receiving SHINGRIX, the patient experienced heart attack (serious criteria GSK medically significant) and product supply issue. On an unknown date, the outcome of the heart attack and product supply issue were unknown. It was unknown if the reporter considered the heart attack to be related to SHINGRIX. Additional information received as follows: The age at vaccination was not reported. The patient's concurrent medical conditions included other complications. The patient went to get the follow up dose only to learn that, there was no supply of SHINGRIX locally. In 2018, the patient had a heart attack. The patient mentioned that, GlaxoSmithKline website states that, there were pharmacies which had the shots, which was false. The patient wanted to get the 2nd dose soon as the patient had scheduled his surgery on 27th November 2018, and the patient had surgery and thought he would be covered prior the surgery. This case has been linked to the case US2018GSK209887, reported by the same reporter.
pt recvd vax & exp a recurrence of pharyngitis, aches in arms & legs; sx persisted for 2 to 3 days; pt returned to MD w/myalgia in arms; t99; mild excoriated, hive-like react w/itching probably due to viral illness;
Patient experienced syncope post vaccination and fell and hit his head. When pharmacist responded, patient was conscious, sitting upright and talking. Patient was transported to emergency room via ambulance.
After the 2nd shot, within 48 hours I had severe Tinnitus in both ears.  Non-pulsatile high pitch.
This spontaneous report as received from a registered nurse refers to a 9 weeks old infant. The patient's concurrent conditions, medical history and drug allergies were not reported. On 15-NOV-2016, the patient was vaccinated with an improperly stored dose of ROTATEQ, oral, (dose not reported) from lot # M014544 with expiry date: 27-NOV-2017 for prophylaxis. Concomitant medications were not reported. The vaccine was exposed to a temperature of 34.5 Fahrenheit for 100 minutes. Data logger was involved. There were no previous excursions. No adverse events were reported. Product quality complaint was not involved. This is one of the several reports received from the same reporter. Additional information is not expected as all follow up information has been received.; Sender's Comments: US-009507513-1610USA008140: US-009507513-1610USA014705:
The day following vaccination the patient experienced typical arm soreness but this was accompanied with a large area of swelling, redness, and warmth around the injection site. Patient also had some body aches which have since resolved. The patient presented to the pharmacy 4 days following vaccination to report the reaction and show the pharmacist. Pharmacist visually examined the arm and observed the swelling and redness. Patient confirmed that these symptoms have been improving. Advised the patient to ice the area and to take an OTC anti-inflammatory if appropriate. Patient will call her doctor if the area worsens or does not improve over the next couple of days.
Dose 1 - soreness at the injection site, achy arm, 8 days after dose a rash appeared at injection site and got worse over 24hrs then subsided after about 5 days  Dose 2 - soreness at the injection site, achy arm, about 12 hrs later started getting full body aches and chills, about 20 hrs after dose had a fever of 104, fever lasted a few hours and broke with a sever sweat, body weakness the next two days
Had covid after 1st vaccine and received second vaccine after. Sis antibody IGG test and I have 1.40 negative for antibodies; This is a spontaneous report from a contactable Other HCP. A 41-years-old non pregnant female patient received second dose of bnt162b2 (COMIRNATY, Lot number: unknown), intramuscularly on left arm 08 Feb2021 15:00 (at the age of 41-year-old) as a single dose as Covid-19 immunisation. It was reported that the patient received first dose of bnt162b2 (COMIRNATY, Lot number: unknown), intramuscularly on left arm 04 Jan2021 15:00 as a single dose as Covid-19 immunisation. Reason why batch/lot is Unknown: misplaced/discarded. The patient's medical history and concomitant medications were not reported. The patient did not receive other vaccine in four weeks, was not diagnosed with COVID-19 prior to vaccination and has not tested for COVID-19 since vaccination. On 25Feb2021 12:00 the patient had covid after 1st vaccine and received second vaccine after. The patient underwent lab test included Sis antibody IGG test and resulted 1.40 negative for antibodies. The outcome of the event was not recovered.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Fever of 105.5F (Rectal) and febrile seizure on 3/3/02 at approx. 12:00. Mom reports that pt was taken ER approx. 19:30, 3/2/02 for fever and treated for the fever. Mom says pt was started on po Augmentin. Pt was then released home. Mom says, "I thought, maybe, he was having a seizure then but was told he wasn't". Mom reports that pt was treated for fever and released home. Mom reports that on 3/3/02 at 01:30 and at approx. 12:00, she took the pt back to ER, "because he was having a seizure". Mom say pt was seen and treated admitted to the hospital. She says pt was given IV fluids and kept on his Augmentin, as well as treated for the fever he had. Mom says, "They said he may have pneumonia, from the CXR". She reports pt was discharged from the hospital on 3/4/02 at approx. 14:00. Mom says pt is still on Augmentin po and she is alternating Tylenol and Motrin q 3 hours. Mom says pt "has had no fever in the past 2 days and has a cough with a runny nose". Mom says pt is to F/U with MD at the end of this week and she has been out of the office. Mom plans to call later in the week to schedule F/U appt.
I received a Pfizer booster for COVID-19 on 8/16/2022. On the evening of 11/27/2022, I had a scratchy throat. On the morning of 11/28/2022, I had a runny nose and a headache; I basically felt like I had a cold. I may have taken some chlorpheniramine, but I don't remember. On 11/29/2022, the symptoms were about the same, only I think my nose ran a bit more. I took a home antigen test, and the result was positive. I called my doctor, who prescribed me Paxlovid, which I started taking around 4-5PM that day. The runny nose continued, but I felt somewhat better on 12/1/2022, because the headache went away, my nose cleared up a little, and I had a bit more energy. I never had a fever during my illness, though. Also, when my husband tested me again on 12/1/2022, the result was still positive. On 12/2/2022 and 12/3/2022, I still tested positive, but the line on the stick was much lighter. I finished the Paxlovid on 12/4/2022, and I continued to test positive. On 12/6/2022, my symptoms worsened. It was a repeat of the cold-like symptoms I had at the beginning, and I had a headache and a nose that wouldn't stop running. I took OTC DayQuil and NyQuil, which helped some, but they didn't completely get rid of the runny nose. These symptoms lasted for the next 7-10 days or so. The headache went away on 12/9/2022 and the runny nose finally went away on by 12/14/2022 or 12/15/2022, and I felt normal again. At the time of this writing, I feel fine, and I have even returned to the gym..
Injection was high on arm and needle hit bone or shoulder joint and was immediately very painful. Within hours the upper arm was sore and continued to be for almost 2 weeks. Now the shoulder area has a burning feel and it's painful in the upper part of the arm when extending the arm forward or upwards. Have not been to see a doctor yet - am hoping with rest and limited use, the shoulder and upper arm will get back to normal.